Introduction
VPF/VEGF is a multifunctional cytokine that is required for tumorigenesis as well as vasculogenesis (1) . It stimulates endothelial cell (EC) proliferation and migration, and increases microvascular permeability (1) (2) (3) (4) . VPF/VEGF functions are mediated, for the most part, by two receptor tyrosine kinases, Flt-1 (VEGFR-1) and KDR (VEGFR-2) (2-6), though it has also been demonstrated that KDR, not Flt-1, is responsible for VPF/VEGF-stimulated proliferation and migration of endothelial cells (EC) (7) (8) (9) (10) (11) . Recently it was shown that Flt-1 activation downmodulates KDR-mediated proliferation using different VPF/VEGF receptor chimeric fusions systems (10, 11) . It also indicated that Flt-1-mediated down-regulation of endothelial cell proliferation through pertussis toxin-sensitive G proteins, Gβγ subunits, small GTPase CDC42 and partly by Rac-1 (11, 12) . A variety of evidence indicates that the activity of phospholipase C (PLC) is required for both EC proliferation and migration, but intracellular Ca 2+ mobilization and MAPK phosphorylation are required for VPF/VEGF-stimulated proliferation of HUVEC, but not migration (11, 13) . However the molecular mechanism by which VPF/VEGF stimulates HUVEC migration is not clear.
The Rho family of the small GTPase superfamily has been shown to play an important role in cell growth, migration, transformation and gene expression (14) . The Rho family includes Rho (A, B, C, E, G), Rac (Rac1, Rac2, Rac3, RhoG) CDC42 (CDC42Hs, G25K, TC10), Rnd (RhoE/Rnd3, Rnd1/Rho6, Rnd2/Rh07), RhoD and TTF (14) . Among them, RhoA, Rac1 and CDC42 are the most extensively studied members of this family. RhoA primarily induces the formation of stress fibers while Rac1 and CDC42 promote the formation of lamellipodia and filopodia, respectively when they were expressed in cells (15, 16) . It was reported that VPF/VEGF induces actin-based mobility (17) , suggesting that Rho family proteins might be involved in this response. Recently, we reported that CDC42 and Rac1 are required and partially required for Flt-1-mediated antiproliferation activity, respectively. However, whether RhoA family members play any role in VPF/VEGF-stimulated HUVEC migration is not known.
In this study, we show that overexpression of dominant negative RhoA, (RhoA-19N) and Rac1 (Rac1-17N) inhibits and partially inhibits VPF/VEGF-stimulated HUVEC migration, respectively. However, overexpression of dominant negative CDC42 (CDC42-17N) has no effect.
Overexpression of RhoA-19N has no effect on intracellular Ca 2+ mobilization and MAPK phosphorylation in VPF/VEGF-stimulated HUVEC.
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Overexpression of proteins in HUVEC. CDC42-17N, Rac1-17N and RhoA-19N were kindly provided by Margaret M. Chou (Univ. of Pennsylvania). The fragments encoding the genes were subcloned to a retroviral vector pMMP (11) . The hβARK1(495) minigene was cloned by RT-PCR from HUVEC RNA and subcloned to a retrovirus vector (18) . Retrovirus preparation and HUVEC infection with retrovirus were carried out as described (11, 13) .
Synthesis and transfection of antisense oligos. 3' end FITC labeled phosphorothioated Gαq/11
antisense oligonucleotide (ODN-Gq/11), 5'-CCATGCGGTTCTCATTGTCTG-3' and a 3' end FITC labeled phosphorothioated random oligonucleotide (ODN-RD), 5'CCCTTATTTACT ACTTTCGC-3' (19) were synthesized by Genemed Synthesis (Genemed Synthesis, South San
Francisco, CA). Transfection was carried out as described (20) .
Migration assays:
Assays were carried out as described (11, 13) . Serum-starved HUVECs (infected with retrovirus or transfected with antisense oligonucleotides) were detached from tissue culture plates as described (11, 13) and washed twice with EBM containing 0.1% FBS, and seeded (1 X 10 5 cells per well) into the transwells coated with vitrogen (30 µg/ml) and the transwells were inserted in a 24-well plate containing 1 ml of the same medium. Cells over a range of 3 x10 3 to 1 x 10 5 cells per well were seeded in a 96-well plate for standard curve. Cells were incubated at 37°C for 1 hr to allow the cells attach, then VPF/VEGF was added at a final concentration of 10 ng/ml.
After incubation for an additional 2 hrs, cells remaining on the upper surface of the transwell filter membrane were wiped off with a cotton tip. The whole transwell membrane was cut out and placed in individual well of the 96-well plate which contains the cells for standard curve. 200 µl of Cyquant DNA stain was added to each well containing cells or membrane and the plate was kept at 4 0 C overnight. After warming to room temperature, stained cells were counted in a spectrofluorometer (SpectraFluor; TECAN) with Delta Soft 3 software. Data are expressed as the mean ± SD of quadruplicate values. All experiments were repeated at least three times.
KDR and MAP kinase phospharylation. Serum-starved HUVECs transduced with LacZ or Rho-19N were treated with 10 ng/ml VPF/VEGF for different time interval as indicated. Cell lysates were either subjected to western blot analysis using an antibody specific for active forms of ERK MAP kinase or immunoprecipitated with an KDR antibody followed by immunoblotting with a phospho-tyrosine antibody as described previously (11, 12) .
Intracellular Ca

2+
-Release. Serum-starved HUVECs transfected with LacZ or RhoA-19N were loaded with Fura-2 AM and stimulated with 10 ng/ml VPF/VEGF. Assay was carried out as described (11, 13) . All experiments repeated at least three times.
RhoA, CDC42 and Rac1 activation assays: The RhoA activity assay was modified from Ren et al. (21) . The glutathione-S-transferase (GST)-Rhotekin Rho binding domain (TRBD) fusion protein was kindly provided by Dr. Martin Schwartz (Scripps Institute). Bacteria were grown to A 600 of 0.8
and induced with 1 mM of isopropylthiogalactoside (IPTG) for 3 hrs. Bacteria were aliquoted per 50 ml and collected by centrifugation at 5000 rpm for 20 min and frozen at -80 o C. To prepare the GST-TRBD beads, each aliquot of 50 ml frozen bacteria was resuspended in 2 ml cold PBS, followed by addition of 20 µl of 1M DTT, 20 µl of 0.2 M PMSF and 40 µl of lysozyme (50 µg/ml).
After incubation on ice for 30 min, 225 µl of 10% Triton X-100, 22.5 µl of 1M MgCl 2 , 22.5 µl of DNAse I (2,000 KU/ml) were added. After another 30 min incubation on ice, the bacteria were centrifuged at 10,000 rpm for 5 min. The supernatant was incubated with 200 µl glutathionecoupled Sepharose 4B beads (Pharmacia Biotech) which were washed with bead washing buffer (PBS with 10 mM DTT and 1% Triton X-100) three times. After incubation at 4 o C for 45 min, beads were washed with bead washing buffer for 3 times and resuspended in the bead washing buffer to give out 50% bead slur.
Twenty-four hours serum-starved HUVEC with or without infection with retrovirus or transfected with antisense oligonucleotides was stimulated with 10 ng/ml VPF/VEGF or EGF for different time interval. Stimulation was stopped by addition of ice-cold PBS. Cells were washed with PBS for three times and lysed with lysis buffer (150 mM NaCl, 0.8 mM MgCl 2 , 5 mM EGTA, 1% IGEPAL, 50 mM HEPES, pH 7.5, 1 µM PMSF, 10 µg/ml leupeptin and 10 µg/ml aprotinin).
Cell lysates were centrifuged at 14,000 rpm for 3 min. The supernatant was incubated with 50 µl GST-TRBD beads at 4 o C for 45 min. Proteins bound to beads were washed trice with AP wash buffer (50 mM Tris-HCl, pH 7.2, 1% triton X-100, 150 mM NaCl, 10 mM MgCl 2 , 1 µM PMSF, 10 µg/ml leupeptin and 10 µg/ml aprotinin) and analyzed by SDS-PAGE. For inhibitors experiments, different concentrations of inhibitors as indicated were added 5 min before EGF treatment. All experiments repeated at least three times.
CDC and Rac1 assays were carried out as described previously (12) . Basely, it is the same as Rho A assay described above, except that GST-Pak-CRIB beads, not GST-TRBD beads, were used. inhibited Flt-1-mediated anti-proliferative activity, respectively, while RhoA-19N has no effect (12) . In this study we further examined whether these dominant negative mutants, CDC42-17N,
Results
Effect
RhoA-19N and Rac1-17N have any effects on VPF/VEGF-stimulated HUVEC migration. CDC42-17N, Rho-19N and Rac1-17N were overexpressed in HUVEC as described previously, with a retrovirus system that demonstrated almost 100% infection yield in HUVEC (11) (12) (13) . Figure 1a shows the expression levels of dominant negative mutants of CDC42-17N, Rac1-17N and RhoA-19N are much higher than those of their corresponding endogenous proteins. HUVEC transduced with CDC42-17N, RhoA-19N and Rac1-17N were serum starved and subjected to migration assay as described elsewhere (11, 13) . The results shows that overexpression of RhoA-19N almost completely inhibits VPF/VEGF-stimulated HUVEC migration. Overexpression of Rac1-17N
inhibits VPF/VEGF-stimulated HUVEC migration by approximately 50%, while overexpression of CDC42-17N has no effect (Fig. 1b) . Figure 1a also (22, 23) . Therefore, we first examined whether RhoA mediates KDR The activity of RhoA was measured by a pull-down assay using a GST-TRBD fusion protein that binds only to the GTP-bound form of RhoA (21) . Serum starved HUVEC were stimulated with VPF/VEGF for different lengths of time as indicated. Cellular extracts were incubated with freshly prepared GST-TRBD beads. Proteins bound to the beads were subjected to western blot analysis using the antibodies against RhoA. Figure 3 shows that RhoA is activated as early as 0.5 min and remains high at 5 min after VPF/VEGF treatment.
In order to systematically study the roles of Rho family GTPases in VPF/VEGF signaling pathways, we used the recently developed receptor chimera (EGDR and EGLT) in which the Nterminal domain of KDR or Flt-1 was replaced with that of EGFR to dissect the signaling pathways mediated by KDR or Flt-1 (11). It was previously shown that HUVEC were not responsive to EGF treatment in the experimental conditions used (11, 12) . As expected, in the HUVEC transduced with LacZ-expressing viruses, EGF did not activate RhoA ( and Rac1 activation. A pull-down assay using the GST-Pak-CRIB fusion protein that binds only to the GTP-bound forms of CDC42 and Rac1 was used to measure the activity of CDC42 and Rac1 (24, 12) . HUVEC transduced with LacZ or EGDR were serum starved and then stimulated with 10 ng/ml EGF for different time intervals as indicated. Cellular extracts were incubated with freshly prepared GST-Pak-CRIB beads. Proteins bound to the beads were subjected to immunoblot analysis using the antibodies against CDC42 or Rac1, respectively. Figures 4b shows that Rac1 is activated in EGDR/HUVEC stimulated with EGF for 0.5 and 1 min. At 5 min EGF stimulation, no Rac1 activation is detected. This EGDR mediated Rac1 activation is in a similar time course to that in VPF/VEGF stimulated HUVEC (12) . However, Figure 4c shows that EGDR cannot mediate CDC42 activation.
The tyrosine 951 of KDR is required for RhoA activation.
Recently, we demonstrated that the tyrosine 951 residue of KDR, which is partially required for KDR phosphorylation, is essential for VPF/VEGF-induced migration but not proliferation (13) . Therefore, we examined whether the EGDR mutant, EGDR (Y951F), has any effect on RhoA and Rac1 activation in HUVEC. HUVEC transduced with EGDR(Y951F) were serum starved and stimulated with 10 ng/ml EGF for different time intervals as indicated. Cellular extracts were subjected to pull down assays with GST-TRBD and GST-Pak-CRIB beads for the measurement of RhoA and Rac1 activation, respectively. As shown in Figure 5 , EGDR(Y951F) can not mediate RhoA activation in response to EGFstimulation, however, the activation of Rac1 in EGF-stimulated EGDR(Y951F)/HUVEC is delayed as compared to that of EGDR/HUVEC (Fig. 4b ). This delay of Rac1 activation in EGDR(Y951F) mutant may be due to its defective phosphorylation activity (13) . These results suggest that the tyrosine 951 residue within KDR is essential for RhoA activation and partially required for Rac1 activation.
In order to identify the signaling molecules that regulate RhoA and Rac1 activation mediated by EGDR. EGDR-transduced HUVEC were pretreated with U73122 (an inhibitor of PLC family), wortmannin and LY294002 (the PI3K inhibitors) or BAPTA/AM (an intracellular Ca 2+ chelator) for 5 min and then treated with EGF for 1 min. Cellular extracts were used to measure the activation of RhoA and Rac1. The data show that both RhoA and Rac1 activation were completely blocked by pretreatment with U73122, however pretreatment with either wortmannin or LY294002
or BAPTA/AM did not inhibit RhoA or Rac-1 activation in EGF-stimulated EGDR/HUVEC ( Fig.   6a and b) . These results indicate that PLC activation is a key intermediary step for EGDR-mediated
RhoA and Rac1 activation.
Gq/11 family proteins and G subunits are required for EGDR-mediated RhoA andRac1
activation. Recently, we reported that pertussis toxin-sensitive G proteins and Gβγ subunits were required for Flt-1-mediated activation of CDC42 and Rac1 (12) . It was also reported that Gq/11
and pertussis-sensitive Gi proteins were found to involved in receptor tyrosine kinases such as insulin receptor, IGF-I receptor and PDGF receptor signaling pathways (25) (26) (27) (28) . Therefore, we tested whether other G proteins, such as Gq/11 family, are involved in KDR-mediated signaling pathway with an antisense oligonucleotide approach. The antisense oligo ODN-Gq/11 was shown to specifically inhibit Gq/11 expression and the function of the delta opioid receptor (19) . With FITClabeled ODN-Gq/11, we showed that HUVEC could be transfected at an efficiency of almost 100%
(data not shown). We first examined whether transfection of ODN-Gq/11 can block Gαq/11 expression in HUVEC. Figure 7a (top panel) shows that ODN-Gq/11 completely blocks Gαq/11 expression (lane 2) whereas the phosphorothioated random oligonucleotide (ODN-RD) does not (Fig. 7a, top panel, lanes 3 ). The blot was stripped and reprobed with an antibody against Gi family proteins to confirm the specificity of ODN-Gq/11 (Fig. 7a, bottom panel) .
EGDR-transduced HUVEC (EGDR/HUVEC) were transfected with or without FITC labeled ODN-Gq/11 or ODN-RD as a negative control. After serum-starvation, cells were stimulated with 10 ng/ml EGF for 1 min. Cellular extracts were subjected to RhoA and Rac1 activation assays. The data show that ODN-Gq/11 completely inhibits RhoA and Rac1 activation, while the control oligo ODN-RD has no effect ( Fig. 7b and c) . These data indicate that Gq/11
proteins are involved in EGDR-mediated RhoA and Rac1 activation. It is known that after activation, heterotrimeric G proteins dissociate into α and βγ subunits that can trigger several downstream signaling pathways (29, 30) . Therefore, to test the role of free Gβγ subunits in EGDRmediated RhoA and Rac1 activation, we used the free Gβγ specific sequestering minigene, hβARK1(495) (31,32). hβARK1(495) contains the C-terminal domain of human βARK1 that physically interacts with free Gβγ subunits and therefore acts as a specific Gβγ antagonist and inhibits Gβγ-mediated downstream events (31,32). . However, RhoA-19N completely inhibits VPF/VEGF-stimulated HUVEC migration, but Rac1-17N just partially inhibits this response (Fig. 1) . Therefore, we examined whether there was any cross talk between RhoA and Rac1. EGDR/HUVEC transduced with LacZ or Rac1-17N was stimulated with EGF for 1 min. Cellular extracts were subjected to a RhoA activation assay. As shown in Fig. 9a , Rac-17N partially inhibits RhoA activation. This partial inhibition of Rho A activation by Rac1-17N is not due to an insufficient infection efficiency as we have shown previously that HUVEC can be easily infected at an efficiency of 100% with our retroviral expression system (11-13). Furthermore, when EGDR/HUVEC transduced with RhoA-19N was stimulated with EGF and cellular extracts were subjected to Rac1 activation assay. RhoA-19N has no effect on Rac1 activation in EGDR/HUVEC stimulated with EGF (Fig. 9b) . These data indicate that KDR-mediated RhoA activation is mediated by Rac1-dependent as well as -independent pathways.
Requirement of Gq/11 proteins and G subunits for VPF/VEGF-stimulated HUVEC migration.
Because Gq/11 and Gβγ subunits are required for KDR-mediated RhoA and Rac1 activation that are required for VPF/VEGF-stimulation, we further tested whether Gq/11 proteins and the Gβγ subunits were required for VPF/VEGF-stimulated HUVEC migration. HUVEC were transfected with the antisense oligo ODN-Gq/11 and the control oligo ODN-RD. After serum starvation, cells were subjected to the migration assay. As shown in Figure 10a , Gq/11 specific antisense oligo ODNGq/11 completely inhibits VPF/VEGF-stimulated HUVEC migration, while the control oligo ODN-RD has no effect. Furthermore, when HUVEC were transduced with LacZ-or hβARK1(495)-expressing viruses, VPF/VEGF-stimulated cell migration was completely inhibited by hβARK1(495) (Fig. 10b) . These results clearly indicate that Gq/11 proteins and Gβγ subunits are required not only for KDR-mediated RhoA and Rac1 activation, but for cell migration in HUVEC stimulated by VPF/VEGF.
Discussion
Most of the VPF/VEGF functions are mediated by its two high affinity receptors, KDR and Flt-1 (2-6). Because both KDR and Flt-1 are expressed in primary ECs, we recently developed chimeric fusion receptors, in which the extracellular domains of KDR and Flt-1 were replaced with that of EGFR, to elucidate the different signaling pathways mediated by these two receptors (11).
Using these chimeric fusion receptors, we found that VPF/VEGF-stimulated CDC42 and Rac1 19N) and Rac1 (Rac1-17N) completely inhibits and partially inhibits VPF/VEGFstimulated HUVEC migration, respectively, but overexpression of the dominant negative mutant of CDC42 (CDC42-17N) has no effect. These results are consistent with the previous observations that KDR, not Flt-1, is responsible for VPF/VEGF-stimulated endothelial cell migration (7-11).
Involvement of Rho family proteins in cell migration has been extensively studied in other systems (33,34). RhoA GTPase is known to induce cytoskeletal reorganization such as the formation of actin-stress fibers and focal adhesion complexes (for review, (35)). VPF/VEGF has also been reported to induce actin-based mobility (17 mobilization, MAPK phosphorylation and proliferation, had no effect on migration (13) . Our results show that RhoA-19N overexpression has no effect on VPF/VEGF-induced intracellular Ca 2+ mobilization and that BAPTA/AM pretreatment (an intracellular Ca 2+ chelator) has no effect on VPF/VEGF-induced RhoA activation. These data further confirm that intracellular Ca 2+ mobilization is not involved in the signaling pathway that leads to VPF/VEGF-stimulated HUVEC migration. Our observations that RhoA-19N overexpression has no effect on VPF/VEGF-stimulated KDR phosphorylation indicating that RhoA may function down-stream of KDR activation. This is further confirmed by EGDR(Y951F), because this KDR mutant partially inhibits EGDR phosphorylation (13), but completely lose its ability to activate Rho A (Fig. 5 ). Interestingly this KDR mutant (Y951F) still
activates Rac1 but at a delayed kinetics as compared to its wild type receptor. One possibility might be that other tyrosine residue(s) of KDR in addition to tyrosine 951 is essential for Rac1 activation mediated by VPF/VEGF. As we described previously, the phosphorylation level of EGDR mutant (Y951F) is much lower than that of wild-type EGF receptor (13) but does not completely diminished, therefore other tyrosine residue(s) might be phosphorylated and activates the pathway in delayed manner. Further studies are required to understand the delayed activation mechanism of Rac1 in KDR Y951F mutant. Taken together our data suggest that tyrosine residue 951 of KDR is essential for Rho activation whereas it is partly required for Rac1 activation.
In summary, our current study has identified a novel signaling pathway which regulates VPF/VEGF-induced migration of HUVEC. In this pathway, KDR stimulation leads to Rho Adependent HUVEC migration through heterotrimeric G proteins Gq/11, free βγ subunits and PLC.
However, the Flt-1-mediated CDC42 and Rac1 activation through pertussis toxin sensitive G proteins, free Gβγ subunit and PI3K is required and partially required for anti-proliferation activity in VPF/VEGF-stimulated HUVEC, respectively (12). Furthermore, both KDR-mediated RhoA and
Flt-1-mediated CDC42 activation are regulated by Rac1-dependent and independent pathways.
These findings further our understanding of the molecular mechanisms by which VPF/VEGF regulates vasculogenesis and angiogenesis and provide additional molecular target for therapeutic purpose.
31. Akhter, S. A., Luttrell, L. M., Rockman, H. A., Iaccarino, G., Lefkowitz, R. J., and Koch, W. J. and Rac1-17N were stimulated with or without 10 ng/ml VPF/VEGF for 2 hrs as described in method section. n =4. 
